May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol, or obesity have a higher likelihood of developing Alzheimer’s disease.

May 25, 2022 — Immune response and the lymphatic system are central to cardiac repair after a heart attack, according to a study from Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg Cardiovascular Research Institute. These insights into the basic mechanisms of cardiac repair are the first step towards developing novel therapeutic approaches to preserve heart function.

May 25, 2022 — Researchers from the group of  Eva van Rooij used advanced sequencing technology to better understand the heart disease arrhythmogenic cardiomyopathy, in which heart muscle tissue is replaced by fat cells.

May 25, 2022 — ŌNŌCOR LLC, a leader in endovascular safety technology, today announced it has received 510(k) U.S. Food and Drug Administration (FDA) clearance for its ŌNŌ retrieval system, the first major advance in endovascular bailout technology in decades. This comes at a time when endovascular closure procedures are rapidly expanding in scope and complexity around the world.

May 25, 2022 — MedStar Heart & Vascular Institute announced that Thomas E. MacGillivray, MD, has been named physician executive director of Cardiac Surgery at MedStar Health, and chairman of Cardiac Surgery at MedStar Washington Hospital Center, effective September 1, 2022.

May 24, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost-effectiveness of VASCEPA (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022, showcased significant potential to reduce major cardiovascular (CV) eve

May 24, 2022 — Attune Medical, a pioneering medical device company with a technology platform based on temperature management using the esophagus, announced today that the first patients have been enrolled in the Improving Oesophageal Protection During Catheter Ablation for Atrial Fibrillation (IMPACT II) Study evaluating the use of the ensoETM in

May 24, 2022 — The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has initiated a voluntary nationwide recall of a single lot of Anagrelide Capsules, USP 0.5 mg (Lot number GD01090), to the consumer level in the United States. This voluntary recall was initiated due to dissolution test failure detected during routine stability testing. No other lots are impacted.

Endovascular Cardiac Complications Congress

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now